The U.S. prenatal genetic testing market, representing over a $2.5 billion annual total addressable market (TAM), offers significant opportunities for healthcare investors in a rapidly growing sector. As testing capabilities expand, understanding how healthcare providers select diagnostic laboratories is crucial for identifying trends and shifts.
A recent survey of 169 obstetrician-gynecologists (OB-GYNs) and maternal-fetal medicine specialists (MFMs) found that clinical accuracy and financial accessibility were the strongest drivers of test selection, cited by 78% of respondents. Providers prioritize tests with low no-call (test failure) rates to ensure reliable results, while patients increasingly seek affordable pricing. Labs that offer broad insurance coverage and minimize out‑of‑pocket costs are better positioned to drive adoption and generate consistent volumes.
Clinical guidelines also play an important role. Recommendations from major medical organizations, such as the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM), influence provider decisions, with 39% of surveyed physicians citing their recommendations as a top factor for test selection. ACOG currently recommends standard cell-free non‑invasive prenatal testing (NIPT) for common chromosomal conditions, while newer single‑gene NIPTs have not yet been endorsed. Among providers familiar with these tests, 55% said updated guidelines would increase their use, underscoring the influence future recommendations could have.
Workflow efficiency is another key differentiator. Many healthcare professionals emphasize the importance of streamlined processes, with 30% of respondents noting that screening for both chromosomal and inherited conditions from a single maternal blood draw is one of the most important factors for their test selection. This combined approach addresses common bottlenecks in traditional carrier screening, which often require paternal genetic testing when the mother is identified as a carrier. In the survey, 51% of providers reported challenges in obtaining paternal samples, and 45% viewed combined screening options as “game-changing” or “very important.” Tests that rely solely on maternal samples address these bottlenecks and improve workflow efficiency.
As the market evolves, companies that prioritize the practical needs of OB-GYNs and MFMs are likely to lead. Accuracy, affordability, workflow efficiency, and guideline support will determine adoption patterns and competitive positioning.
For investors, these dynamics underscore the importance of monitoring the market and identifying adaptable companies. Success will hinge on the ability to scale while remaining responsive to shifting clinical recommendations.
For more information on related investment opportunities and insights, read Dx Trends: Prenatal Genetics Proprietary Survey of 169 Ob-Gyns and MFMs, published on February 12, 2026, by William Blair healthcare research analyst Andrew F. Brackmann, CFA.